Skip to main content
Top
Published in: Malaria Journal 1/2012

Open Access 01-10-2012 | Oral presentation

Estimating the window of selection of antimalarial drugs using field data

Authors: Katherine Winter, Ian Hastings

Published in: Malaria Journal | Special Issue 1/2012

Login to get access

Excerpt

Drug resistance spreads through a population because (i) parasites can survive direct treatment and/or (ii) survive “residual” drug levels persisting from previous treatment. High levels of drug use and long drug half-lives mean a high proportion of the population may have residual drug levels selecting for resistance. Field studies can quantify this second force of resistance by estimating a window of selection (WoS); a period of time during which drug levels have declined sufficiently to allow new infections with drug resistant parasites while still able to prevent infections by drug sensitive parasites. Typically this is estimated by comparing how early different genotypes become detectable after treatment. These WoS estimates are widely cited and we refer to them as ‘apparent’ WoS to denote their origin in clinical observations. In fact the ‘true’ WoS is the period in which infections bearing the mutation can emerge from the liver and survive to produce a patent infection while sensitive parasites are killed by residual drug concentrations. Unfortunately, it is impossible to observe this emergence because parasites (assuming 105 emerge) are below the microscopic limit of detection (assumed to be 108) and so we are forced to rely on ‘apparent’ WoS i.e., the time at which they have grown to patency. …
Literature
1.
go back to reference Winter K, Hastings IM: Development, evaluation and application of an in silico model for antimalarial drug treatment failure. Antimicrob Agents. 2011, 55: 3380-3392. 10.1128/AAC.01712-10.CrossRef Winter K, Hastings IM: Development, evaluation and application of an in silico model for antimalarial drug treatment failure. Antimicrob Agents. 2011, 55: 3380-3392. 10.1128/AAC.01712-10.CrossRef
Metadata
Title
Estimating the window of selection of antimalarial drugs using field data
Authors
Katherine Winter
Ian Hastings
Publication date
01-10-2012
Publisher
BioMed Central
Published in
Malaria Journal / Issue Special Issue 1/2012
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-11-S1-O33

Other articles of this Special Issue 1/2012

Malaria Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.